Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The objective of this study is to assess the bioequivalence of the test product, Exemestane 25 mg tablets of Actavis Group PTC ehf. Iceland, and the reference product, Aromasin® (exemestane) 25 mg tablets of Pharmacia \& Upjohn Company, Division of Pfizer Inc., New York, United States of America in healthy male and postmenopausal female subjects, under fasting conditions
Epistemonikos ID: 48e39af49a7d25765dd6cd01567848682761bafc
First added on: May 11, 2024